Here, we investigated the functional role of LOXL3 in GBM using CRISPR-Cas9-mediated LOXL3 knockdown in two genetically distinct GBM cell lines: U87MG (wild-type <i>TP53</i>) and U251 (mutant <i>TP53</i>). Here, LOXL3 is linked to glioblastoma.